CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
Símbolo de cotizaciónCVRX
Nombre de la empresaCVRx Inc
Fecha de salida a bolsaJun 30, 2021
Director ejecutivoMr. Kevin Hykes
Número de empleados206
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 30
Dirección9201 West Broadway Avenue
CiudadMINNEAPOLIS
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal55445
Teléfono17634162850
Sitio Webhttps://www.cvrx.com/
Símbolo de cotizaciónCVRX
Fecha de salida a bolsaJun 30, 2021
Director ejecutivoMr. Kevin Hykes
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos